Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Scpharmaceuticals Inc is a biotechnology business based in the US. Scpharmaceuticals shares (SCPH) are listed on the NASDAQ and all prices are listed in US Dollars. Scpharmaceuticals employs 26 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $4.88 |
|---|---|
| 52-week range | $3.48 - $7.24 |
| 50-day moving average | $4.77 |
| 200-day moving average | $5.20 |
| Wall St. target price | $10.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.05 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.88 from 2022-07-01
| 1 week (2022-06-28) | 1.67% |
|---|---|
| 1 month (2022-06-02) | 4.05% |
| 3 months (2022-04-05) | -24.69% |
| 6 months (2022-01-01) | N/A |
| 1 year (2021-07-02) | -30.19% |
|---|---|
| 2 years (2020-07-02) | -31.84% |
| 3 years (2019-07-05) | 39.03% |
| 5 years (2017-07-01) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -19.45% |
| Return on equity TTM | -45.9% |
| Profit margin | 0% |
| Book value | $1.81 |
| Market capitalisation | $133.6 million |
TTM: trailing 12 months
We're not expecting Scpharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Scpharmaceuticals's shares have ranged in value from as little as $3.48 up to $7.24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Scpharmaceuticals's is 0.4245. This would suggest that Scpharmaceuticals's shares are less volatile than average (for this exchange).
scPharmaceuticals Inc. , a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.